Related by context. All words. (Click for frequent words.) 74 Montgomery Asberg Depression 73 ADAS Cog 72 Alzheimer Disease Assessment 70 Secondary endpoints included 70 ADAS cog 70 Scale cognitive subscale 70 Primary endpoints 70 Rating Scale MADRS 70 WOMAC TM 70 DLQI 69 Neuropsychiatric Inventory NPI 69 Negative Symptoms 69 achieved statistical significance 69 Negative Syndrome 69 Fibromyalgia Impact Questionnaire 69 WOMAC pain 69 Scale EDSS 68 YMRS 68 Scale PANSS 68 Brief Psychiatric 68 Crohn Disease Activity 68 clinically meaningful improvement 68 Index CDAI 68 Secondary endpoints include 68 Montgomery Åsberg Depression 68 morphometric vertebral fractures 68 QIDS SR 68 prednisone prednisolone plus 68 Global Impression CGI 68 haematologic 68 symptom severity 68 Unified Parkinson Disease 68 UPDRS motor 67 DAS# CRP 67 Severity MSCS score 67 function subscale 67 ADHD Rating Scale 67 moderate renal impairment 67 HOMA IR 67 HAQ DI 67 euthymic patients 67 Inventory BPI 67 prespecified secondary 66 left ventricular diastolic 66 nasal symptom 66 baseline HbA1c 66 Psoriasis Area 66 Symptom severity 66 PANSS total 66 glycosylated hemoglobin HbA1c 66 CINQUIL 66 HAMD 66 PANSS 66 venlafaxine XR 66 attain statistical significance 66 NIHSS 66 serum phosphorous 66 Tasigna prolongs 66 bronchial hyperresponsiveness 66 ACTEMRA TM 66 Rating Scale UPDRS 66 Skin sterol 66 International Prostate Symptom 66 Visual Analogue Scale VAS 66 elevated ALT 65 Loss Severity 65 SGRQ 65 echocardiographic parameters 65 oxycodone CR 65 achieved ACR# 65 -#.# mg dL [002] 65 PLX STROKE targeting 65 NNT = 65 affective psychosis 65 hematological parameters 65 Pharmacokinetic parameters 65 8mg/kg 65 depressive symptom 65 Mean Symptom Complex 65 mild renal insufficiency 65 Scale Cognitive Subscale 65 hemodynamic measurements 65 serum aminotransferase levels 65 abdominal pain abdominal discomfort 65 -#.# mg dL [001] 65 PASI scores 65 NYHA functional class 65 ADCS ADL 65 Y BOCS 65 hyperphenylalaninemia HPA due 64 Interrater reliability 64 confirmed CCyR 64 Secondary endpoints 64 aspartate aminotransferase AST 64 Pain Intensity 64 Health Assessment Questionnaire 64 tipranavir r 64 ADHD RS 64 fasting plasma glucose FPG 64 demonstrated clinically meaningful 64 glycated hemoglobin HbA1c 64 HDRS 64 CIMZIA TM certolizumab pegol 64 glycated hemoglobin levels 64 prospectively stratified 64 MMSE score 64 clinically meaningful improvements 64 EORTC QLQ C# 64 glycosylated hemoglobin levels 64 NIH CPSI 64 CIBIC plus 64 CIMZIA ™ 64 AST ALT 64 Non inferiority 64 BMI z 64 liver histology 64 Endothelial function 64 Cystic Fibrosis Questionnaire Revised 64 HbA 1c levels 64 CONCERTA ® 64 MADRS score 64 4mg/kg 64 SGPT 64 clinically meaningful reductions 64 extrapyramidal symptoms 64 baseline A1C 64 corticosteroid dose 64 hemoglobin A1c HbA1c 64 intima media thickness 64 Global Impression 64 BPH symptom 64 Hamilton Anxiety Scale 64 infliximab monotherapy 64 relapsed MM 64 MADRS 64 paliperidone ER 64 Maintain Equal Weight 64 receiving XGEVA 64 INVEGA ® 64 Expanded Disability Status 64 -#.# log# copies mL 64 Severity Index PASI 64 MoxDuo TM IR 63 certolizumab 63 HER2 expression 63 reduce serum phosphate 63 CNS LS 63 Capacity FVC 63 ATACAND 63 rosuvastatin #mg 63 BENICAR HCT 63 headache nasopharyngitis 63 Scale EDSS score 63 Cardiorespiratory fitness 63 opioid naïve 63 linaclotide treated 63 symptomatic VTE 63 comorbid anxiety 63 indicates cardio circulatory 63 somatostatin analog 63 subthreshold depression 63 SSRI SNRI 63 IRLS 63 albumin excretion rate 63 pulmonary capillary wedge 63 IBDQ 63 Ocular Surface Disease 63 Hamilton Rating Scale 63 UPDRS 63 PANSS Positive 63 plus prednisone prednisolone 63 budesonide pMDI 63 myocardial infarction ventricular fibrillation 63 clinicopathological features 63 antidepressants fluoxetine 63 GERD symptom 63 tissue oxygenation 63 BEXXAR Therapeutic Regimen 63 intraobserver 63 tapentadol ER 63 Status Scale EDSS 63 PSA nadir 63 aMCI precursor 63 #mg/day [002] 63 GAMMAGARD 63 Index CDAI score 63 pain subscale 63 DAS# [002] 63 Secondary efficacy endpoints 63 Q#IR 63 Oral NKTR 63 psychosocial functioning 63 DAS# remission 63 plus methotrexate 63 mg TID 63 baseline serum creatinine 63 HbA1C levels 62 WOMAC 62 unresectable HCC 62 desvenlafaxine succinate 62 anaphylactic reactions bronchospasm 62 mg BID dose 62 tonsillar hypertrophy 62 HRQL 62 posttest 62 TNSS 62 Score TOS 62 Hb A1C 62 primidone 62 RECIST Response Evaluation Criteria 62 Persistent Sleep 62 EDSS scores 62 CIMZIA TM 62 nicardipine 62 intact parathyroid hormone 62 exhaled NO 62 Visual Analog Scale 62 opioid naive 62 urine albumin 62 intima media thickness IMT 62 urinary N telopeptide 62 Known hypersensitivity 62 non menstrual pelvic 62 NIS LL 62 intravascular hemolysis 62 spirometric 62 NIHSS score 62 NPH insulin 62 ULORIC 62 serum urate 62 calculated creatinine clearance 62 hsCRP levels 62 inhaled iloprost 62 CYP#A# substrate 62 #q# deletion syndrome 62 elevated IOP 62 AUA Symptom Score 62 XIENCE V PROMUS Stent 62 Glasgow Coma Scale 62 Visual acuity 62 blood Phe levels 62 elevated transaminases 62 STRIDE PD 62 EDEMA3 trial 62 Glomerular Filtration Rate 62 CDAI score 62 mcg QD 62 HAM D 62 BENICAR 62 glomerular filtration 62 premorbid 62 CYP#A# CYP#D# 62 elevated creatinine 62 concomitant medications 62 ACR# ACR# 62 Score IPSS 62 SSRI citalopram 62 IRLS score 62 ARB telmisartan 62 neutropenia thrombocytopenia 62 carotid IMT 62 sUA 62 RoACTEMRA 62 MAGE A3 ASCI 62 aldosterone antagonist 62 BPH Symptom Score 62 hemoglobin A1c levels 62 subjective sleepiness 62 aminotransferases 62 overt nephropathy 62 #.#/#.# mmHg [001] 62 % Confidence Interval 62 ACR# response 62 S# Hybrid mileage 62 FluCAM arm 62 recombinant PSMA vaccine 62 CR nPR 62 postintervention 62 Clinically significant 62 secondary efficacy endpoint 62 Naive Patients 62 fluticasone salmeterol 62 prospectively defined 62 abnormal clotting 62 arterial oxygen saturation 62 Rating Scale BPRS 62 CCyR 62 treat NNT 62 systemic corticosteroid 62 HbA1C 62 vitreous floaters 62 EQ 5D 62 hemoglobin A1C HbA1C 62 Atkins dieters cardiovascular 62 methotrexate monotherapy 62 Mg Uk 62 hemodynamically significant 62 LV dysfunction 62 TNF Tumor Necrosis Factor 62 conditional logistic regression 62 abacavir lamivudine 62 CIBIC + 62 State Examination MMSE 62 variant angina 62 preintervention 61 erection hardness 61 HAM D# 61 salmeterol fluticasone 61 weekly CSBMs 61 Erythropoietic therapies may 61 carotid intima media 61 aplindore 61 postprocedure 61 fasting plasma glucose 61 Viral load 61 recurrent glioblastoma multiforme 61 TMS Therapy 61 atorvastatin #mg 61 evaluating tivozanib 61 SELENA SLEDAI 61 schizophrenia schizoaffective disorder 61 Ejection Fraction 61 HRQoL 61 Mg Usa 61 mg Proellex 61 humanized interleukin 6 61 serum BDNF 61 deep venous thromboses 61 preoperative PSA 61 quetiapine Seroquel 61 APOE genotype 61 NATRECOR ® 61 FOLFOX6 61 colesevelam HCl 61 pulmonary exacerbations 61 systemic immunosuppressive drugs 61 Score DAS 61 TAXUS p value 61 plasma leptin 61 PANSS scores 61 AGILECT R 61 Tumor Response 61 Interferon beta 1b 61 SYNERGY Stent 61 sorafenib tablets 61 dactylitis 61 deCODE AF TM 61 autonomic dysfunction 61 mcg BID 61 lopinavir r arm 61 ARCALYST ® 61 placebo p = 61 severe exacerbations 61 coronary stenosis 61 carotid artery blockage 61 Neuropsychiatric Inventory 61 PEGINTRON TM 61 lipid parameters 61 oral antidiabetes 61 Prognostic significance 61 Teriflunomide 61 oral antidiabetic medication 61 QTc prolongation 61 dermatologic toxicities 61 estimated glomerular filtration 61 depression suicidal ideation 61 tamoxifen Nolvadex ® 61 multi infarct dementia 61 ALIMTA cisplatin 61 teriflunomide 61 FOLFOX6 chemotherapy regimen 61 neurocognitive function 61 #mg dose [002] 61 plasma creatinine 61 statistical significance p 61 tirofiban 61 mL/min/#.# m 2 61 serum urate levels 61 pharmacodynamic PD 61 PSQI 61 serum IGF 61 #mg/day [001] 61 Engerix B 61 dose pravastatin 61 approved incretin mimetic 61 endoscopic remission 61 unresectable tumors 61 zonisamide SR 61 glycoprotein IIb IIIa inhibitor 61 aspirin clopidogrel 61 arterial thromboembolic events 61 symptom exacerbation 61 galiximab 61 CYT# potent vascular disrupting 61 Beck Anxiety Inventory 61 pharmacodynamic parameters 61 hematopoietic cancers 61 β blocker 61 VELCADE melphalan 61 subscore 61 lumbar disk herniation 61 Ishak fibrosis score 61 xanthine oxidase inhibitor 61 #.#mg/dL 61 HBeAg seroconversion 61 prognostic indicators 61 Key secondary endpoints 61 HIV HCV coinfected 61 eNO 61 Main Outcome Measure 61 lispro 61 Main Outcome Measures 61 mRS 61 C Reactive Protein 61 Sustained virologic response 61 Flu Cy 61 IOP lowering 61 Pain Rating Scale 61 thyrotropin levels 61 CDAI 61 mucosal healing 61 Desvenlafaxine Succinate 61 dose proportionality 61 azilsartan medoxomil 61 mitoxantrone plus 61 HMG CoA reductase inhibitors 60 Fasting glucose 60 mTSS 60 chronic idiopathic thrombocytopenic purpura 60 REMINYL ® 60 Seattle Angina Questionnaire 60 Reiterates outperform 60 elevated triglyceride levels 60 icatibant 60 QTcF 60 unstable angina pectoris 60 evaluating Actimmune 60 PREZISTA r arm 60 acute mania 60 sensitivity specificity 60 Zometa hazard 60 artery stenosis 60 microbiological eradication 60 C1 INH deficiency 60 gp# vaccine 60 serum triglycerides 60 Insulin sensitivity 60 EDARBI 60 DAS# scores 60 STRATEGY FOR AN OPEN 60 emotional lability 60 CPAP adherence 60 hemoglobin A1C 60 multivariate Cox 60 annualized relapse 60 Vildagliptin 60 mm Hg diastolic 60 antipsychotic efficacy 60 quetiapine XR 60 CFQ R 60 interferon gamma 1b 60 EDEMA3 60 subsyndromal 60 meta regression 60 posttreatment 60 epoetin alpha 60 AUA BPH Symptom Score 60 Treatment Outcome 60 plus COPEGUS 60 mcg kg REBETOL 60 APACHE II 60 IPSS 60 dose Iluvien 60 atrioventricular block 60 ViaDerm hPTH #-# 60 biochemical relapse 60 PsA 60 cerebral somatic oximeter 60 CRp 60 x ULN 60 PITX2 methylation 60 vaginal progesterone gel 60 Brief Pain 60 electrophysiologic 60 ZOLINZA 60 mild hepatic impairment 60 mg XP# 60 pharmacokinetic equivalence 60 serum phosphate 60 psychosocial variables 60 clomipramine 60 glomerular filtration rate 60 Sensitivity specificity 60 clinico pathological 60 sustained virological response 60 colorectal adenoma 60 SpO2 pulse rate 60 tolterodine ER 60 bortezomib refractory 60 log# copies mL 60 serum potassium 60 alanine aminotransferase ALT 60 R entecavir 60 baseline PASI 60 retinal thickness 60 GSK# [001] 60 NSAID associated 60 Postoperatively 60 RAPAFLO R 60 PCWP 60 Coronary artery calcium 60 UPDRS scores 60 Change PGIC 60 carboplatin chemotherapy 60 HES CEL 60 biopsy Gleason 60 Cystatin C 60 INVEGA ™ 60 UPDRS Part III 60 antiarrhythmic drug 60 sargramostim 60 Atomoxetine 60 inflammatory biomarkers 60 non squamous histology 60 drotrecogin alfa activated 60 CI -#.# 60 oxcarbazepine 60 Score DAS# 60 hepatic enzyme 60 ARCOXIA 60 comorbid disorders 60 concurrent ITP 60 extrapyramidal side 60 ecchymosis 60 A1c levels 60 cTnT levels 60 lactate dehydrogenase LDH 60 hematologic parameters 60 postoperative complication 60 Hematologic toxicity 60 Hyperlipidemia 60 transaminase elevations 60 HRQOL 60 enthesitis 60 Doxil ® 60 Keeps outperform 60 rheumatoid arthritis osteoarthritis ankylosing 60 TWYNSTA 60 leucopenia 60 oral levofloxacin 60 angiographic outcomes 60 VIIBRYD 60 Demonstrated Significant 60 inattention hyperactivity 60 fructosamine 60 adjunctive placebo 60 neutropenic fever 60 aPTT 60 autoantibody positive 60 TLUS 60 maximal doses 60 arterial stenosis 60 â ‰ ¥ 60 Infusion Reactions Severe 60 Amgen Neulasta R 60 TRIOLEX HE# APOPTONE HE# 60 highly emetogenic 60 obstructive CAD 60 6MWD 60 FOLFIRI alone 60 insomnia somnolence 60 Natalizumab 60 serologically active patients 60 oral FTY# 60 FUSILEV enhances 60 serum parathyroid hormone 60 lumbar spine BMD 60 melphalan prednisone 60 HIV coinfected 60 exploratory endpoints 60 adjunctive ABILIFY 60 anemia hemoglobin 60 mucosal inflammation 60 visceral adiposity 60 overnight polysomnography 60 thrombocytopenia anemia 60 genotypic resistance 60 subscores 60 hormone receptor negative 60 affective psychoses 60 plasma renin activity 60 achieving PASI 60 Rosenberg Self Esteem 60 PRADAXA #mg 60 QoL 60 sulfonylurea metformin 60 benazepril 60 convergent validity 60 NMIBC 60 fraction LVEF 60 blood Phe 60 unstable angina UA 60 nonhematologic adverse reactions 60 bioprosthetic valve 60 Bosentan 60 statistically significant efficacy 60 surrogate endpoint 60 BARACLUDE ® 60 convulsive disorders 60 Ashworth Scale 60 multivariate logistic regression 60 cerebral oxygenation 60 plus MTX 60 Histologic 60 MMSE 60 paroxetine sertraline 60 perceptual reasoning 59 Refractory Hodgkin Lymphoma 59 mg ustekinumab 59 myocardial viability 59 abnormal lipid 59 mean ± SEM 59 minimally symptomatic 59 Apolipoprotein B 59 antiplatelet medications 59 completely resected 59 Kaplan Meier estimates 59 FOLPI 59 activated partial thromboplastin 59 clinical endpoints 59 Subgroup analysis 59 tiagabine 59 pain palliation 59 pharmacokinetic PK profile 59 hepatic insufficiency 59 methacholine challenge 59 headache abdominal pain 59 aplastic anemia AA 59 Clinician Administered PTSD 59 Pioglitazone 59 glulisine 59 bone marrow reticulin deposition 59 SCr 59 severe gastroparesis 59 fasting insulin 59 weekly subcutaneous injections 59 atherogenic dyslipidemia 59 pressure tachycardia diaphoresis 59 TAXUS Express Stent 59 left ventricular systolic 59 receiving VELCADE 59 multivariable adjusted 59 Sodium oxybate 59 pooled comparator 59 LAB CGRP 59 CrCl 59 Physical Function 59 bivalirudin monotherapy 59 Warfarin Coumadin 59 lowest tertile 59 Scale CNS 59 bronchoalveolar lavage fluid 59 systemic hypotension 59 fatigue abdominal pain 59 Zemplar Capsules 59 PSADT 59 ACR# [002] 59 MACUGEN 59 Suicidal ideation 59 CANCIDAS 59 comorbid depression 59 Hill Rom enhancing 59 leukocyte count 59 divalproex sodium 59 BPRS 59 psychiatric comorbidity 59 CIBIC Plus 59 Pegasys ® 59 balsalazide 59 catheter occlusion 59 subscale scores 59 neutropaenia 59 baseline FEV 59 Fasting plasma glucose 59 Pharmacodynamic 59 statistically significant superiority 59 Dementia Related Psychosis 59 Bronchopulmonary Dysplasia 59 MCyR 59 PEGylated anti 59 idiopathic Parkinson disease 59 trough FEV1 59 glycosylated hemoglobin 59 PROCTOCORT ® Suppository Hydrocortisone 59 ionotropic 59 Hypertrophy 59 QTc 59 reactogenicity 59 daytime somnolence 59 Vidaza ® 59 Glomerular filtration rate 59 Zoloft sertraline 59 System IPSS 59 noninvasive outpatient 59 Rating Scale IRLS 59 CORE OM 59 unfractionated heparin UFH 59 EDSS 59 oral diclofenac 59 Platelet counts 59 Geriatric Depression 59 unfavorable cytogenetics 59 tapentadol IR 59 tranylcypromine 59 bronchodilatory 59 intracranial atherosclerosis 59 GH deficiency 59 recurrent ischemia 59 candesartan cilexetil 59 novel VDA molecule 59 Heterozygous Familial Hypercholesterolemia 59 MDS MPD 59 recovery CRp 59 generalized anxiety disorder GAD 59 euthymic 59 aminotransferase levels 59 low dose Iluvien 59 Univariate 59 virologic responses 59 Cardiopulmonary bypass 59 receiving TNF blockers 59 R# #mg BID 59 CTAP# Capsules 59 apnea hypopnea index 59 ETDRS 59 LDL triglycerides 59 IMiDs ® compound 59 anagrelide 59 mmol l 59 Rating Scale 59 platelet reactivity 59 NeuroMove TM 59 0 Thumbs Up 59 warfarin erythromycin 59 mesalamine granules 59 eszopiclone 59 HbA 1C 59 corrected QT interval 59 Depression Inventory 59 Acute Coronary Syndromes ACS 59 serum cortisol 59 dose atorvastatin 59 oral rivaroxaban 59 HBeAg negative patients 59 plus octreotide LAR 59 biochemical recurrence 59 neurologic progression 59 Lewy bodies DLB 59 Cardiac Resynchronization 59 EXJADE 59 FOLFOX4 59 multivariate analyzes 59 CHADS2 59 alfuzosin 59 creatinine clearance 59 Disease Activity 59 haemodynamic 59 severely active polyarticular 59 pyridostigmine 59 PROTECT II 59 metabolic alkalosis 59 lipid lowering agents 59 chronic progressive neurodegenerative 59 airway hyperresponsiveness 59 systolic function 59 FFR measurements 59 AGILECT ® 59 permanently discontinue Vectibix 59 Endothelial dysfunction 59 containing abacavir 59 Fasting blood glucose 59 anticholinergic agents 59 cardiac autonomic 59 HCV antibody 59 antibody titer 59 symptomatic hyponatremia 59 impaired glucose metabolism 59 Shows Statistically Significant 59 antidiabetic medications 59 P = .# 59 Echocardiographic 59 diabetes mellitus DM 59 r hGH 59 antiangiogenic agent 59 neutropenia fatigue 59 hormone receptor status 59 prolactin levels 59 novel synthetic PEGylated 59 receiving golimumab 59 Kinesia 59 moderate hepatic impairment 59 NPM1 mutation 59 3mg/kg 59 Uncontrolled hypertension 59 daytime alertness 59 Efficacy endpoints 59 HSCT 59 Numeric Rating Scale 59 carotid stenosis 59 octreotide LAR 59 Oral Fingolimod 59 histologic subtype 59 Interferon beta 1a 59 Retisert TM 59 mg QD 59 unexplained syncope 59 apolipoprotein B 59 selective modulator 59 poststroke 59 undetectable HBV DNA 59 EDSS score 59 peak VO2 59 #.#mmHg 59 EGFr expressing metastatic colorectal 59 brand ciclesonide HFA 59 ACR# responses 59 ANCOVA 59 % CI #.#-#.# [007] 59 elevated fasting glucose 59 endoscopic gastric ulcers 59 transaminases 59 Paliperidone ER 59 PEG IFN 59 cognitive affective 59 MMSE scores 59 posttransplant 59 obstructive coronary artery 59 VaD 59 NATRECOR R 59 comparator arm 59 exhaled nitric oxide 59 perioperatively 59 p = .# [002] 59 CP CPPS 59 nausea dizziness vomiting 59 6R BH4 59 Demonstrate Significant 59 radiotherapy RT 59 mg p = 59 mg kg Hematide 59 sham injections 59 quetiapine risperidone 59 irbesartan 59 Newly Diagnosed Multiple Myeloma 59 prolactin elevation 59 lymphocyte count 59 Angiotensin receptor blockers 59 neuropathy sensory 59 cerebral perfusion 59 elevated serum creatinine 59 warfarin sodium 59 Cholinesterase Inhibitors 59 Lantus ® 59 histological subtype 59 urate lowering therapy 59 coronary revascularization procedures 58 -#.# log# 58 transcranial Doppler ultrasound 58 interferon beta therapy 58 LDH lactate dehydrogenase 58 argatroban 58 Operative mortality 58 1mg dose 58 receiving INTRON 58 hyaluronidase enzyme 58 Cimzia TM 58 Erectile function 58 basal bolus regimen 58 ratio ICER 58 plasma triglycerides 58 Pseudomonas aeruginosa P. aeruginosa 58 serum phosphate levels 58 ejection fractions 58 esophageal candidiasis 58 Avandia Actos 58 interrater reliability 58 phonophobia 58 Hypotension 58 pegaptanib 58 Long Term Efficacy 58 induced macular edema 58 conventional DMARDs 58 undergoing elective percutaneous 58 pathophysiological effects 58 left ventricular LV 58 neutropenic sepsis 58 hemostatic efficacy 58 carotid artery intima media 58 chronic thromboembolic pulmonary 58 postoperative morbidity 58 nonfatal myocardial infarction MI 58 nonvertebral fracture 58 postoperative AF 58 nondiabetic patients 58 mild renal impairment 58 complete cytogenetic response 58 Methotrexate MTX 58 pericardial effusion 58 neurocognitive functioning 58 HbA1c levels 58 pharmacodynamic profiles 58 compulsive hoarding syndrome 58 mg kg BID 58 neurosensory 58 Maintained Buy 58 diastolic blood pressures 58 alanine aminotransferase 58 ACTOplus met XR 58 Ziprasidone 58 Creatinine 58 Descriptive statistics 58 peripheral sensory neuropathy 58 Xalatan R 58 dapagliflozin plus 58 TMP SMX 58 Stent thrombosis 58 mean baseline A1C 58 DexaSite 58 ICD shocks 58 log# IU mL 58 Ribavirin causes 58 hepatic enzymes 58 metabolic parameters 58 Severe hypoglycemia 58 mmHg diastolic 58 ritonavir boosted 58 antiretroviral naïve 58 either acutely decompensated 58 Ejection fraction 58 anginal pain 58 valsartan amlodipine 58 Mania Rating Scale 58 RLAI 58 lymphopenia 58 thromboembolic 58 SF #v# 58 mU liter 58 Vimpat R 58 DOXIL 58 BARACLUDE r 58 Meets Primary Endpoint 58 noncardiovascular mortality 58 concomitant cardiac 58 ug dose 58 Erectile Function IIEF 58 adenotonsillectomy 58 placebo fluoxetine 58 multivariate adjustment 58 severe hepatic dysfunction 58 constipation nausea 58 folinic acid 58 Visual Analog 58 ACR Pedi 58 rufinamide 58 Patients Receiving 58 shorter telomere length 58 statistically significant p = 58 Postoperative 58 IMiDs ® 58 TURBT 58 vascular occlusive diseases 58 odds ratios ORs 58 triple nucleoside regimen 58 hsCRP 58 pioglitazone HCl 58 mg/# hours 58 artery elasticity 58 LDL cholesterol HDL cholesterol 58 pharmacodynamic effects 58 multivariable Cox 58 macroalbuminuria 58 Ophena TM 58 Depressive symptoms 58 triglyceride concentration 58 EEG abnormalities 58 insulin detemir 58 sustained virologic response 58 Tekamlo 58 Depression Rating Scale 58 SIMPADICO 58 SSc 58 oral prednisolone 58 autoantibody levels 58 briakinumab 58 PSA kinetics 58 sociodemographic characteristics 58 Hormone receptor 58 fatal anaphylactic 58 apremilast